Article

System uses cooled therapy to treat BPH symptoms

Urologix, Inc., offers the Prostatron System, which is designed to reducethe symptoms and obstruction due to BPH by delivering a controlled doseof microwave energy to the prostate without damaging the urethra or surroundingstructures. The system delivers microwave energy to the prostate transurethrallythrough a specially designed treatment catheter that encases a tiny microwaveantenna.

Related Videos
Perry Xu, MD, answers a question during a Zoom video interview
Helen L. Bernie, DO, MPH, answers a question during a Zoom video interview
Kate H. Kraft, MD, MHPE, FACS, FAAP, answers a question during a Zoom video interview
John P. Mulhall, MD, answers a question during a Zoom video interview
Related Content
Avoidance of prostate cancer screening linked to increased risk of PCSM
March 21st 2025

Avoidance of prostate cancer screening linked to increased risk of PCSM

Hannah Clarke
“Our study identifies that men who were invited for screening, but do not attend screening appointments are at significantly higher risk of dying from prostate cancer compared to men who were not offered screening or accepted an invitation for screening,” says Renée Leenen MD.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Closeup financial chart with uptrend line candlestick graph in stock market on blue color monitor background | Image Credit: © iamchamp - stock.adobe.com
March 21st 2025

Money Matters: How to cope with market volatility in 2025

Jeff Witz, CFP
"If you determine you can invest in a volatile environment, the best approach is to do so over a period of time," writes Jeff Witz, CFP.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Trial launches of CBP/p300 inhibitor in mCRPC
March 20th 2025

Trial launches of CBP/p300 inhibitor in mCRPC

Hannah Clarke
Pocenbrodib is an oral, small molecule designed to inhibit the proteins CREBBP/EP300, which activate genes that promote cancer cell growth and proliferation.
Nadofaragene firadenovec maintains safety, efficacy in real-world population
March 20th 2025

Nadofaragene firadenovec maintains safety, efficacy in real-world population

Mark D. Tyson, MD, MPH Jacob A. Moyer, BS Hannah Clarke
"The implication for real-world decision-making is that this drug appears to hold up to what was seen in the trial," says Mark D. Tyson II, MD, MPH.
© 2025 MJH Life Sciences

All rights reserved.